Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

Metabo-Oncology: The Latest Frontier in Cancer Research

There is a new field of cancer research that is only just now starting to take shape but is promising to greatly increase our understanding of cancer and what can influence how it develops over time. This field is being called metabo-oncology.

Read More

SynDevRx launches Metabo-Oncology.com website

Metabo-Oncology press release 26Mar 2019 FINAL

Read More

SDX at AACR: Obesity confers immuno-suppressive tumor microenvironment – Poster Presentation

April 1, 8:00 AM to 12:00 PM 1226 / 4 – A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME)

Read More

Increasing cancer rates among young adults tied to obesity

Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endometrial, gallbladder, kidney and pancreatic.

Read More

Dr. Lewis Cantley, PhD on the role of insulin in PI3K resistance

Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.

Read More

Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer

Cancer patients who are obese face a greater risk of dying from cancer compared to non-obese patients (Calle, 2003). Excess visceral adiposity is believed to contribute to metastasis and progression of cancer via multiple mechanisms: increased secretion of the adipose tissue hormone leptin, decreased secretion of adiponectin, increased production of estrogen in adipose tissue, and elevated insulin (secondary to peripheral insulin resistance) as well as the local effects of inflammatory cytokines (Gucalp, 2016).

Read More

Diabetes Increases Breast Cancer Mortality Risk

Women with breast cancer and diabetes have a greater risk for all-cause and cancer-specific mortality and are less likely to receive chemotherapy and radiotherapy compared with women with breast cancer alone, according to researchers.

Read More

40 percent of US cancers linked to excess weight

About 40 percent of all cancers in the United States -- more than 630,000 in all -- are associated with excess weight, health officials said Tuesday, urging a renewed focus on prevention. The rates of these overweight- and obesity-related cancers are rising, in contrast to the overall rate of new cancer cases which has dropped since the 1990s.

Read More

ESMO 2017 Press Release: Abdominal Fat a Key Cancer Driver for Postmenopausal Women

"When assessing cancer risk, body mass index (BMI) and fat percentage may not be adequate measures as they fail to assess the distribution of fat mass," she explained. "Avoiding central obesity may confer the best protection."

Read More

Throwing oil into the flames

Obesity has become one of the lead­ing preventable causes of cancer. Yet, the mechanisms of how obesity and associated systemic inflammation can promote cancer progression remain poorly understood. In a new study, researchers found that the cytokines interleukin 5 (IL-5) and granulocyte macrophage colony-stimulating fac­tor (GM-CSF) are induced in obesity and, in obese mice, this leads to lung neutrophilia and supports breast cancer metastasis to the lung. Quail, Olson et al. used mouse models of obesity, induced by a high-fat diet (diet-induced obesity, DIO mice) or leptin deficiency (ob/ ob mice), to study how inflammation in obesity is linked to breast cancer metastasis.

Read More